Among the anti-tumor effects of regorafenib, this TKI could modulate the autophagy pathway to counteract tumor cell survival [31], but the effect of regorafenib on FOXO3 and autophagy regulation in sorafenib-resistant HCC has not been studied yet. The gene discussed is FOXO3; the disease is neoplasm.